X

Drug Profile

NMI 221

Alternative Names: Moxisylyte-SNO; S-Nitrosylated moxisylyte; SNO-moxisylyte

Latest Information Update: 19 Mar 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NitroMed
Developer Boston University School of Medicine; NitroMed
Class Nitroso compounds; Small molecules
Mechanism of Action Alpha adrenergic receptor antagonists; Nitric oxide donors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Erectile dysfunction

Most Recent Events

06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
22 Oct 1999 A preclinical study has been added to the adverse events and pharmacodynamics sections
28 Sep 1999 Preclinical development for Erectile dysfunction in USA (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com